Allergic rhinitis (AR) is a type-I hypersensitivity disease mediated by immunoglobulin E (IgE). Although antihistamines, glucocorticoids, leukotriene receptor antagonists, and other drugs are widely used to treat AR, the various adverse side effects of long-term use of these drugs should not be ignored. Therefore, more effective and safe natural alternative strategies are urgently needed. To this end, this study designed a nanosupramolecular delivery system composed of β-cyclodextrin supramolecular polymer (PCD), thiolated chitosan (TCS), and natural polyphenol epigallocatechin gallate (EGCG) for intranasal topical continuous treatment of AR. The TCS/PCD@EGCG nanocarriers exhibited an excellent performance in terms of retention and permeability in the nasal mucosa and released the vast majority of EGCG responsively in the nasal microenvironment, thus resulting in the significantly high antibacterial and antioxidant capacities. According to the in vitro model, compared with free EGCG, TCS/PCD@EGCG inhibited mast cell activity and abnormal histamine secretion in a more long-term and sustained manner. According to the in vivo model, whether in the presence of continuous or intermittent administration, TCS/PCD@EGCG substantially inhibited the secretion of allergenic factors and inflammatory factors, mitigated the pathological changes of nasal mucosa, alleviated the symptoms of rhinitis in mice, and produced a satisfactory therapeutic effect on AR. In particular, the therapeutic effect of TCS/PCD@EGCG systems were even superior to that of budesonide during intermittent treatment. Therefore, the TCS/PCD@EGCG nanocarrier is a potential long-lasting antiallergic medicine for the treatment of AR.

中文翻译：

---

EGCG 超分子组装用于长期治疗过敏性鼻炎

过敏性鼻炎（AR）是一种由免疫球蛋白E（IgE）介导的I型超敏反应疾病。尽管抗组胺药、糖皮质激素、白三烯受体拮抗剂等药物被广泛用于治疗AR，但长期使用这些药物的各种不良副作用也不容忽视。因此，迫切需要更有效、更安全的天然替代策略。为此，本研究设计了一种由β-环糊精超分子聚合物（PCD）、硫醇化壳聚糖（TCS）和天然多酚表没食子儿茶素没食子酸酯（EGCG）组成的纳米超分子递送系统，用于鼻内局部连续治疗AR。 TCS/PCD@EGCG纳米载体在鼻粘膜保留和渗透性方面表现出优异的性能，并在鼻腔微环境中响应释放绝大多数EGCG，从而具有显着高的抗菌和抗氧化能力。根据体外模型，与游离EGCG相比，TCS/PCD@EGCG以更长期、持续的方式抑制肥大细胞活性和异常组胺分泌。体内模型显示，无论是连续给药还是间歇给药，TCS/PCD@EGCG均显着抑制过敏因子和炎症因子的分泌，减轻鼻粘膜病理变化，减轻小鼠鼻炎症状，对AR产生了满意的治疗效果。特别是，TCS/PCD@EGCG系统在间歇治疗期间的治疗效果甚至优于布地奈德。因此，TCS/PCD@EGCG纳米载体是治疗AR的潜在长效抗过敏药物。